Fig. 1From: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trialEVATAT flow diagram. This flow diagram was constructed according to CONSORT recommendation [41]Back to article page